ArticleJournal of gastrointestinal oncology2024

Regorafenib combined with a PD-1 inhibitor in the second-line setting for unresectable hepatocellular carcinoma in real-world practice.

Huaqiang Bi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.